Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?